1. Home
  2. KOPN vs XFOR Comparison

KOPN vs XFOR Comparison

Compare KOPN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KOPN
  • XFOR
  • Stock Information
  • Founded
  • KOPN 1984
  • XFOR 2014
  • Country
  • KOPN United States
  • XFOR United States
  • Employees
  • KOPN N/A
  • XFOR N/A
  • Industry
  • KOPN Semiconductors
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KOPN Technology
  • XFOR Health Care
  • Exchange
  • KOPN Nasdaq
  • XFOR Nasdaq
  • Market Cap
  • KOPN 138.4M
  • XFOR 118.4M
  • IPO Year
  • KOPN 1992
  • XFOR N/A
  • Fundamental
  • Price
  • KOPN $1.43
  • XFOR $3.37
  • Analyst Decision
  • KOPN Strong Buy
  • XFOR Strong Buy
  • Analyst Count
  • KOPN 4
  • XFOR 3
  • Target Price
  • KOPN $2.56
  • XFOR $72.33
  • AVG Volume (30 Days)
  • KOPN 2.2M
  • XFOR 145.5K
  • Earning Date
  • KOPN 05-16-2025
  • XFOR 05-01-2025
  • Dividend Yield
  • KOPN N/A
  • XFOR N/A
  • EPS Growth
  • KOPN N/A
  • XFOR N/A
  • EPS
  • KOPN N/A
  • XFOR 2.16
  • Revenue
  • KOPN $50,335,167.00
  • XFOR $31,364,000.00
  • Revenue This Year
  • KOPN $8.75
  • XFOR $355.69
  • Revenue Next Year
  • KOPN $24.15
  • XFOR $140.28
  • P/E Ratio
  • KOPN N/A
  • XFOR $1.55
  • Revenue Growth
  • KOPN 24.61
  • XFOR N/A
  • 52 Week Low
  • KOPN $0.56
  • XFOR $3.05
  • 52 Week High
  • KOPN $2.17
  • XFOR $34.20
  • Technical
  • Relative Strength Index (RSI)
  • KOPN 66.87
  • XFOR 22.18
  • Support Level
  • KOPN $1.24
  • XFOR $3.05
  • Resistance Level
  • KOPN $1.38
  • XFOR $3.41
  • Average True Range (ATR)
  • KOPN 0.09
  • XFOR 0.62
  • MACD
  • KOPN 0.04
  • XFOR -0.02
  • Stochastic Oscillator
  • KOPN 98.09
  • XFOR 8.94

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: